NCT05615623 2026-04-21
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG
InSightec
Phase 1/2 Active not recruiting
InSightec
InSightec
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
Children's Oncology Group
Memorial Sloan Kettering Cancer Center